NASDAQ:GRAL GRAIL (GRAL) Stock Price, News & Analysis $80.77 +0.82 (+1.03%) Closing price 04:00 PM EasternExtended Trading$80.96 +0.19 (+0.23%) As of 07:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About GRAIL Stock (NASDAQ:GRAL) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get GRAIL alerts:Sign Up Key Stats Today's Range$78.20▼$82.8550-Day Range$63.40▼$82.5452-Week Range$39.29▼$118.84Volume3.00 million shsAverage Volume700,928 shsMarket Capitalization$3.61 billionP/E RatioN/ADividend YieldN/APrice Target$70.30Consensus RatingHold Company Overview GRAIL, Inc. is a healthcare company focused on developing blood-based tests for the early detection of cancer. Its technology uses genomic and epigenomic signals, including patterns of DNA methylation, to identify signals associated with multiple cancer types from a single blood sample. The company’s primary product is Galleri, a prescription blood test designed to screen for signals of more than 50 types of cancer, including cancers that currently lack recommended screening methods. Galleri is intended to complement, not replace, guideline-recommended cancer screenings, and a positive result requires follow-up diagnostic testing to determine whether cancer is present and where it may be located. GRAIL was founded in 2016 as a subsidiary of Illumina and became an independent publicly traded company following its separation from Illumina in 2021. The company is headquartered in Menlo Park, California, and primarily serves the U.S. market. GRAIL has also participated in research and commercial initiatives involving health systems, employers, and international partners to evaluate the use of multi-cancer early detection testing.AI Generated. May Contain Errors. Read More GRAIL Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks15th Percentile Overall ScoreGRAL MarketRank™: GRAIL scored higher than 15% of companies evaluated by MarketBeat, and ranked 849th out of 905 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.2 / 5Analyst RatingHold Consensus RatingGRAIL has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on no strong buy ratings, 5 buy ratings, 6 hold ratings, and 1 sell rating.Downside RiskGRAIL has a consensus price target of $70.30, representing about 13.0% downside from its current price of $80.77.Amount of Analyst CoverageGRAIL has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about GRAIL's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for GRAIL are expected to decrease in the coming year, from ($10.41) to ($10.70) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of GRAIL is -8.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of GRAIL is -8.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGRAIL has a P/B Ratio of 1.22. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about GRAIL's valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted19.41% of the float of GRAIL has been sold short.Short Interest Ratio / Days to CoverGRAIL has a short interest ratio ("days to cover") of 12.28, which indicates bearish sentiment.Change versus previous monthShort interest in GRAIL has recently increased by 4.38%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldGRAIL does not currently pay a dividend.Dividend GrowthGRAIL does not have a long track record of dividend growth. News and Social Media2.9 / 5News Sentiment0.67 News SentimentGRAIL has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 16 news articles for GRAIL this week, compared to 9 articles on an average week.Search InterestOnly 1 people have searched for GRAL on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows2 people have added GRAIL to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, GRAIL insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,096,679.00 in company stock.Percentage Held by Insiders1.83% of the stock of GRAIL is held by insiders.Percentage Held by InstitutionsGRAIL has minimal institutional ownership at this time.Read more about GRAIL's insider trading history. Receive GRAL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for GRAIL and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. GRAL Stock News HeadlinesGRAIL Risk-Reward Attractive Ahead of FDA Advisory Committee, UBS SaysSeptember 18 at 6:18 PM | finance.yahoo.comRBC Capital initiates coverage of GRAIL at sector performSeptember 18 at 8:14 AM | msn.com$40,000,000,000,000The national debt just hit 40 trillion dollars, and the U.S. now spends more on interest payments than on its entire military budget. Central banks have bought over 1,000 tonnes of gold a year for three years running, trading paper for metal.September 18 at 1:00 AM | American Alternative (Ad)RBC Initiates GRAIL at Sector Perform With $84 Price TargetSeptember 17 at 2:47 PM | marketscreener.comMGrail's Galleri Test Has Large Market Potential Amid Adoption Curve Concerns, RBC Capital Markets SaysSeptember 17 at 2:47 PM | finance.yahoo.comUBS Initiates a Buy Rating on GRAIL Inc (GRAL)September 15 at 7:48 AM | theglobeandmail.comGRAIL, Inc. (GRAL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeptember 14, 2026 | seekingalpha.comGRAIL (NASDAQ:GRAL) CEO Sells 5,000 SharesSeptember 1, 2026 | insidertrades.comSee More Headlines GRAL Stock Analysis - Frequently Asked Questions How have GRAL shares performed this year? GRAIL's stock was trading at $85.59 on January 1st, 2026. Since then, GRAL shares have decreased by 5.6% and is now trading at $80.77. How were GRAIL's earnings last quarter? GRAIL, Inc. (NASDAQ:GRAL) announced its quarterly earnings results on Wednesday, August, 5th. The company reported ($2.56) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($2.66) by $0.10. The business had revenue of $44.69 million for the quarter, compared to analysts' expectations of $42.39 million. GRAIL had a negative net margin of 236.95% and a negative trailing twelve-month return on equity of 15.88%. Read the conference call transcript. Who are GRAIL's major shareholders? Top institutional investors of GRAIL include BlackRock Inc. (8.33%), Primecap Management Co. CA (4.88%), Arbiter Partners Capital Management LLC (2.32%) and Bank of America Corp DE (1.62%). Insiders that own company stock include Chun R Ding, Robert P Ragusa, Joshua J Ofman, Aaron Freidin and Andrew John Partridge. View institutional ownership trends. How do I buy shares of GRAIL? Shares of GRAL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of GRAIL own? Based on aggregate information from My MarketBeat watchlists, some other companies that GRAIL investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Meta Platforms (META), Netflix (NFLX), JPMorgan Chase & Co. (JPM) and Visa (V). Company Calendar Last Earnings8/05/2026Today9/18/2026Next Earnings (Estimated)11/11/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 GRAL's financial health is in the Green zone, according to TradeSmith. GRAL has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:GRAL Previous SymbolNASDAQ:GRAL CIK1699031 Webgrail.com Phone(833) 694-2553FaxN/AEmployees910Year Founded2016Price Target and Rating Average Price Target for GRAIL$70.30 High Price Target$84.00 Low Price Target$56.00 Potential Upside/Downside-13.0%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage12 Analysts Profitability EPS (Trailing Twelve Months)($9.75) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$408.35 million Net Margins-236.95% Pretax Margin-320.38% Return on Equity-15.88% Return on Assets-14.02% Debt Debt-to-Equity RatioN/A Current Ratio10.95 Quick Ratio10.95 Sales & Book Value Annual Sales$147.17 million Price / Sales24.52 Cash FlowN/A Price / Cash FlowN/A Book Value$66.13 per share Price / Book1.22Miscellaneous Outstanding Shares44,670,000Free Float43,849,000Market Cap$3.61 billion OptionableOptionable Beta3.25 Social Links The Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free Report This page (NASDAQ:GRAL) was last updated on 9/18/2026 by MarketBeat.com Staff. From Our Partners$40,000,000,000,000The national debt just hit 40 trillion dollars, and the U.S. now spends more on interest payments than on its ...American Alternative | SponsoredA “bloodbath” Is ComingReports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the co...TradeSmith | SponsoredThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...Traders Agency | SponsoredShocking new footage just releasedGerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...Digest Publishing | SponsoredIran War WARNING: Something Just ChangedA powerful Middle Eastern government is reportedly asking Trump for U.S. military help against Iran backed for...Banyan Hill Publishing | SponsoredWhy I went to Mount RushmoreA small miner just hit on gold in the hills surrounding Mount Rushmore, thanks to a breakthrough new technolog...Stansberry Research | SponsoredMy next big call (under $1)17,556% on KDA. Here's what I'm buying now. It's a coin under $1.00 that most investors have never heard of...Crypto 101 Media | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GRAIL, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share GRAIL With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
